+44 (0)1865-842-976 (UK)

+91 20 30108 270 (ASIA)

Cellular therapies hold the potential to revolutionize health care for a variety of diseases. However, the limitations lie in the productivity of engineered cells and the safe, efficacious and cost effective transformation of commercialized cell therapies. The industry is yet to address certain gaps relating to these limitations that will facilitate clinical and commercial success of these therapies. The aim of the conference is to assess the risks and benefits of the cell culture and cell therapy bio-manufacturing by focusing in particular on the feasibility of process automation: its impact on regulatory compliance and return on investment.

MarketsandMarkets has put together a unique platform to establish the reproducible and robust manufacturing processes for the production of stable cell culture and therapeutic cells. At the Cell Culture & Cell Therapy: Bioprocessing Conference scheduled to be held in Philadelphia, USA on 26 - 27 June 2017, leading experts in the industry will be gathered to discuss strategies, technologies and innovations in the area of bioprocessing of cell culture and cell-gene therapies.

conference Registration Form



Academic Delegate$399
Industry Delegate $599
Industry Delegate (Early Bird) - 31st March 2017$499
Academic Delegate (Early Bird) - 28th February 2017$299


Key Highlights

  • Fermentation technologies
  • Device technologies for bioprocessing of cell culture
  • Next generation cellular models
  • Optimization of cell culture process
  • Closed system manufacturing of cells
  • Process development for next generation bio-therapeutics
  • Ex-vivo gene therapy application
  • Compatibility and stability of cell therapy products
  • Automation process development and control
  • C-GMP compliance guidelines
  • FDA approvals and regulatory policies
  • Commercialized view of bioprocessing
  • Insurance and reinvestment policies

Who Should Attend ?

From Pharmaceuticals, biopharmaceuticals and therapeutics based companies:

Engineers/Scientists/Researchers/Project leaders/VPs/Heads in:

  • Bioprocess development
  • Cellular Therapy
  • Gene Therapy
  • Therapeutics
  • Pharmacology
  • Therapeutics
  • Quality Control
  • Biotherapeutics
  • Cell Engineering
  • Regulatory affairs


From Universities and Research Institutes:

Scientists/Professors/Researchers/Project leaders in

  • Bioprocessing
  • Biochemistry
  • Bioengineering
  • Biomaterials
  • Chemical Engineering
  • Molecular Biology
  • Material Sciences
  • Pharmacology
  • Biotechnology
  • Cell therapy
  • Gene therapy
  • Cell culture
  • Cell Engineering

Advisory Panel

  • Dr. J Joseph Melenhorst
    Director, Product Development & Correlative Sciences laboratories
    Penn Medicine, University of Pennsylvania
  • Dr. Scott R. Burger
    Advanced Cell & Gene Therapy, LLC
  • Dr. Benjamin Fryer
    Team Leader, CMC, Cardiomyocyte Cell Manufacturing
    University of Washington



  • Dr. Robert Nerem

    Institute Professor Emeritus, Georgia Institute of Technology
  • Dr. Robert Dream

    Managing Director, HDR Company LLC
  • Dr. Scott R. Burger

    Principal, Advanced Cell & Gene Therapy, LLC
  • Dr. Timothy Laden

    Director, Tissue and Cellular Innovation Center Biology Department, University of Wisconsin-River Falls
  • J Joseph Melenhorst

    Director, Product Development & Correlative Sciences laboratories, Penn Medicine, University of Pennsylvania
  • Dr. Benjamin Fryer

    Team Leader, CMC, Cardiomyocyte Cell Manufacturing, University of Washington
  • Dr. Juliana Woda

    Project Manager, BioMotiv
  • Dr. Piret James

    Professor, The University of British Columbia
  • Dr. Qasim Rafiq

    Assistant Professor, Aston University
  • Dr. Chris Albanese

    Director, Preclinical Imaging Research Laboratory (PIRL), Georgetown University Medical Center
  • Dr. John M. Baust

    President and CEO, CPSI Biotech
  • Dr. Tiffany D Rau

    Head of Technical Operations, Evonik
  • Dr. Aby J. Mathew

    Sr. Vice President & Chief Technology Officer, BioLife Solutions
  • Dr. Nathan E. Lewis

    Assistant Professor, University of California, San Diego
  • Dr. Andrew D Fesnak

    Assistant Professor of Clinical Pathology and Laboratory Medicine, University of Pennsylvania
  • Dr. Ravinder Bhatia

    Scientific Director, Johnson & Johnson
  • Dr. Knut Niss

    Asset Leader Cell Therapies- Director PO&T, Biogen
  • Dr. Govind Dhanasekaran

    Lead-Virology (Upstream process development), Merck
  • Dr. Dawn Maier

    Associate Director-Cellular Process Development, Bluebird Bio
  • Biren Mistry

    Senior Engineer-Bioprocess Development, Celgene
  • Jamal Meghrous

    Cell culture specialist, Protein Sciences, Inc.
  • David Schaffer

    Professor, Chemical and Biomolecular Engineering, University of California at Berkeley
  • Dr. Joseph J. Pancrazio

    Associate Provost-Professor, Department of Bioengineering, The University of Texas at Dallas
  • Dr. Jeffrey Bartlett

    Chief Scientific Officer, Calimmune Inc.
  • Garth D. Ehrlich

    Executive Director, Drexel College of Medicine
  • Dr. Jonathan M. Shillingford

    Associate Director-Cell Biology, Endocyte Inc
  • Yvonne A. Reid

    Sr. Scientist, ATCC, Virginia
  • Susan Celia Roberts

    Professor, Chemical Engineering, Worcester Polytechnic Institute, Massachusetts
  • Adrian P. Gee

    Professor of Medicine & Pediatrics, Center for Cell & Gene Therapy, Baylor College of Medicine, Texas
  • Dr. Adam Elhofy

    Chief Scientific Officer, Essential Pharmaceuticals LLC.


Gold Sponsor

Essential PharmaceuticalsEssential Pharmaceuticals

Essential Pharmaceuticals  offers Cell-Ess.  Added to any CHO media in large scale bioproduction, it boosts protein yield >25%, increases cell productivity and maintains consistent glycosylation profiles. Manufactured under cGMP. Device master file available.  100% synthetic, chemically defined, low lot-to-lot variation, animal component free. Let Cell-Ess bring control to your process.

MarketsandMarkets provides a variety of direct and indirect marketing and networking opportunities for sponsors and exhibitors. 

All refreshment breaks and lunches take place in the main exhibition ensuring that exhibitors enjoy maximum time to meet and network with senior level attendees. 

Speaking and Workshop Opportunities

  • 15 minute small company showcase presentations.
  • 30 minute presentations on the main conference programme.
  • 25 minute satellite symposiums.
  • 60 minute presentation / workshop on the main conference programme.

Please enquire for pre and post events workshop options. 

Pre-arranged One-on-Meetings
Prearranged one-on-one meetings ensure that you have personal time with your choice of delegates. Twenty minute meetings take place during refreshment breaks. Full delegate profiles are provided prior to the conference to ensure that onsite, you meet with relevant delegates who are truly interested in your products and services. Meetings can take place on your exhibition or in your own private meeting area. 

Pre-event Support
MnM Conferences provide full service pre-event marketing and branding support. Opportunities available include: 

  • Your logo and company description on the event website.
  • Your logo on all marketing materials as a sponsor.
  • Pre-event email shots to attending delegates to increase your onsite exposure.
  • Articles about your products and services in our monthly event newsletter.

For sponsorship opportunities please contact Ajay Nimbalkar at ajay.nimbalkar@marketsandmarkets.com


The United Kingdom Society for Biomaterials (UKSB)United Kingdom Society for Biomaterials (UKSB)

The United Kingdom Society for Biomaterials (UKSB) was set up to serve the diverse, interdisciplinary biomaterials research community. This was in response to the findings of a joint working party of the Institute of Materials and the Institute of Physics & Engineering in Medicine. The UKSB is the democratic Society for the whole biomaterials community.

Global Institute of Stem Cell Therapy and Research (GIOSTAR)Global Institute of Stem Cell Therapy and Research (GIOSTAR)

GIOSTAR is a coalition of esteemed and illustrious scientific minds in the field of stem cell science, genetics and cancer research. GIOSTAR Chairman Dr. Anand Srivastva is credited for starting and establishing the field of stem cell science at the top universities of U.S.A. For over 15 years, GIOSTAR team of scientists and clinicians have been involved in the development and utilization of stem cell based clinical protocols related to stem cell transplants.

Biotech Research Society, India is a non-profit, scientific, professional society dedicated to promote excellence and competence in the field of biotechnology for the benefit of mankind.

Irish Stem Cell FoundationIrish Stem Cell Foundation

The Irish Stem Cell Foundation is an independent, non-profit medical research charity. Established in October 2009, it is composed of researchers, clinicians, patients advocates, patients, science communicators, bioethicists, lawyers, teachers, and students.

BioPharma Research CouncilBioPharma Research Council

The BioPharma Research Council is a nonprofit association for scientists, IT experts, entrepreneurs, and business professionals across all the many silos of biomedical research. Our mission is to foster collaboration and communication among professionals in industry, academia, nonprofit, government, and supplier labs in the biotech/biopharma space. Through conferences, symposia, webinars, Meetups, and committees, the BRC offers engaging in educational content to its community of more than 10,000 scientists, researchers, engineers, and industry experts each year. Many of these programs were suggested and developed through the energy and expertise of members of our community. Have an idea? Be in touch! info@biopharmaresearchcouncil.org


To support Cell Culture & Cell Therapy: Bioprocessing Conference, please contact Ajay Nimbalkar t ajay.nimbalkar@marketsandmarkets.com


For more information on the venue of the conference, you can write to us at events@marketsandmarkets.com